We report the characterization of a rare chromosomal translocation, a t(2;11)(q31;p15), which occurred in a patient with de novo acute myeloid leukemia (AML-M4). By 3Ј-RACE and RT-PCR analyses, two kinds of NUP98-HOXD13 fusion transcript were detected. In addition, we identified a novel fusion transcript, NUP98-FN1, in the same patient. Ectopic expression of the wild-type HOXD13 gene was also observed in the patient, suggesting that HOXD13 contributes to the development of this type of leukemia. The NUP98-HOXD13 fusion transcript was predicted to encode a 552 or 569-amino acid protein containing the Phe-Gly (FG) repeat region of NUP98 and the homeodomain of HOXD13. The NUP98-FN1 fusion transcript was predicted to encode a 482 or 499-amino acid protein consisting of the same N-terminal region of NUP98 and a C-terminal region of 12 amino acids derived from a previously unidentified sequence. We isolated and characterized the chromosomal breakpoints. The breakpoint at 11p15 is mapped within a LINE repetitive element in a 9 kb intron of NUP98, and more than 60% of the sequenced 3 kb region surrounding the breakpoint junction consists of repetitive elements. The other breakpoint at 2q31 is in an intron of FN1, which is located 7 kb upstream of HOXD13, and the repetitive sequence content of the breakpoint junction is low. Local sequence duplications at genomic breakpoints suggest that the t(2;11) translocation is mediated through staggered double-strand DNA breaks. These results throw light on the mechanisms responsible for the generation of t(2;11) translocation and on the processes leading to t(2;11) leukemia. Leukemia (2000) 14, 1621-1629.
Introduction
Chromosomal translocations have been recognized as important events in the pathogenesis of hematopoietic malignancies. 1, 2 Chromosomal abnormalities involving 11p15 have been reported in several hematopoietic disorders. The nucleoporin gene NUP98 at 11p15 was first reported as a fusion gene with HOXA9 in de novo AML (FAB M2 and M4) with the translocation t(7;11)(p15;p15). 3, 4 The NUP98 gene encodes a 98 kDa nucleoporin. It was originally isolated as a component of the nuclear pore complex (NPC). 5 The NPC promotes selective bidirectional transport of protein and RNA between the nucleus and cytoplasm. 6 The N-terminal FG repeat rich domain of NUP98 is thought to provide contact sites for nucleocytoplasmic transport factors. 5 We previously reported the isolation of a fusion gene between NUP98 and a putative RNA helicase gene DDX10 at the breakpoint region of inv(11)(p15q22), which occurs in de novo and therapy-related 
AML/MDS (t-AML/t-MDS)
. 7 More recently, NUP98 was shown to fuse with a variety of genes in a number of balanced translocations: a homeobox gene HOXD13 in one case of childhood t-AML (FAB M6) with t(2;11)(q31;p15); 8 a homeobox gene PMX1 in one case of t-AML (FAB M2) with t(1;11)(q23;p15); 9 the topoisomerase 1 gene TOP1 in two cases of t-MDS with t(11;20)(p15;q11); 10 and a guanine nucleotide exchange factor gene RAP1GDS1 in three cases of Tcell ALL (FAB L1 and L2) with t(4;11)(q21;p15).
11 NUP98 is preferentially involved in therapy-related leukemia. 12 Characterization of the translocation breakpoints of NUP98 and other fusion partner genes is expected to provide important clues about the molecular mechanism of these leukemic translocations.
In this study, we show that the t(2;11) translocation generates heterogeneous chimeric transcripts between NUP98 at 11p15 and genes at 2q31 via intergenic splicing and alternative splicing in de novo AML with t(2;11)(q31;p15). In this AML, the chromosomal translocation occurred within the NUP98 gene and a previously unidentified gene which we named FN1. As a result of this translocation, two types of fusion transcripts, NUP98-HOXD13 and NUP98-FN1, were produced, and the normal allele of the HOXD13 gene was expressed ectopically. By restriction mapping and sequence analysis, we have determined that FN1 is located upstream and close to HOXD13. We also describe genomic sequence analyses of the chromosomal breakpoints of this leukemia.
Materials and methods

Patient material
A 62-year-old-man was diagnosed as having AML (FAB M4). Leukemia cells were obtained from the patient at diagnosis. Flow cytometric analysis showed cell surface marker expression of CD11b
− , and HLA-DR + . Cytogenetic analysis of the sample showed a karyotype of 46, XY, and t(2;11)(q31;p15). He received BHAC-DMP chemotherapy, a standard Japanese protocol against AML, including the following anticancer agents; behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and predonisolone. The patient has been in complete remission for 6 years without any relapse. Materials were obtained from the patient with informed consent.
PCR primers
The nucleotide sequences of all the PCR primers used in this study are listed in Table 1 . The localizations of most primers are shown schematically in Figure 4 . Table 1 PCR primers used in this study Primer  Gene  Sequence (5Ј-3Ј)  name   NH17  NUP98 ATGTTTAACAAATCATTTGGAACACCCTTTGG  GGGT  Hxd13H1 HOXD13 TCAGGAGACAGTATCTTTGAGCTTGGA  NXF3  NUP98 CCTATTTTCCCTGGTATTAC  NXR3  NUP98 ATTTTCACACAAGTCCCTAA  NF98  NUP98 TTTGGCAATAACAAGCTTACTAC  NR106 NUP98 CCCCAAAGGCTCCTGTACCAAGA  A  NUP98 GGGAATAGTATTTTTGGAAGTAA  B  NUP98 TCTTGGTACAGGAGCCTTTGGGG  C  NUP98 CAAAAGCATTTAGGATTGTCC  D  NUP98 GGTGAAACCCCATCTCTACTT  E  NUP98 TCTTCTTAGGGTCTGACATCGGA  F  FN1  CGCGCCTCCAAACGGAAAT  G  FN1  GAGGAGGGAGGGGAAAATCTG  H  FN1  CTCCGCGTCCCATCCCCGTCCTC  I  FN1  CCGCTCCTCATCTCCCGCGGTTG  J  FN1  TCTCGAGCTTGCCCCCTAACACA  K  HOXD13 CATTGCTGACTTTTGCCTTCTTTTC  L  HOXD13 CTACTACAGCTGCCGTATGTCG  M  HOXD13 GCGCCTCCTCCCTCCTCTCCTTT  N  HOXD13 CTAAATCAGCCGGACATGTG  O  HOXD13 AAGCTGTCTGTGGCCAACC  AP1  CCATCCTAATACGACTCACTATAGGGC  AP2  ACTCACTATAGGGCTCGAGCGGC  LM1 GCGGTGACCCGGGAGATCTGAATTC
Southern blot analysis
Genomic DNA (5 g) was digested with appropriate restriction enzymes, separated by 0.8% agarose gel electrophoresis, transferred on to a Hybond-N membrane (Amersham-Pharmacia, Uppsala, Sweden). Hybridization with radio-labeled probes was performed at 42°C in 6x standard saline citrate (SSC)/10% dextran sulfate/1% SDS/1x Denhardt's solution/50% formamide) containing denatured salmon sperm DNA (100 g/ml). Autoradiography was performed using a bioimage analyzer, BAS2000 (Fujifilm, Tokyo, Japan).
3Ј-RACE and sequencing
3Ј-rapid amplification of cDNA ends (RACE) was performed using the Marathon cDNA Amplification Kit (Clontech, Palo Alto, CA, USA) and a modified protocol as described previously. 13 In brief, 1 g of total RNA was isolated from leukemia cells. From this RNA, cDNA was synthesized with random nonamer primers or oligo dT primer, and was ligated with a cDNA adaptor. PCR amplification was performed using the NUP98 exon 11-specific forward primer A and adaptorspecific primers AP1 and/or AP2. PCR products were separated by electrophoresis through a 1.5% GTG agarose gel (FMC Bioproducts, Rockland, ME, USA) in 1ϫ TAE. Fragments were excised from the gel and sequenced directly. Chromosome mapping of the 3Ј-RACE products was performed by PCR using two kinds of somatic cell hybrid panels; 
Reverse transcription-polymerase chain reaction (RT-PCR)
From 1 g of total RNA, cDNA was synthesized in 20 l of reaction mixture containing random primers by using the Thermo Script RT-PCR system (Gibco BRL, Gaithersburg, MD, USA). The mixture was diluted to 40 l and 1 or 2 l was used for PCR. PCR amplification was carried out for 35 cycles (denaturation at 94°C for 20 s, annealing at 55 or 60°C for 40 s, and extension at 72°C for 60 s), followed by denaturation at 94°C for 2 min and extension at 72°C for 5 min using a GeneAmp PCR system 9600 (Perkin Elmer, Foster City, CA, USA). PCR products were separated by electrophoresis through a 1.5% GTG agarose gel. Fragments were excised from the gel and subcloned into the pGEMT vector (Promega, Madison, WI, USA), and plasmid clones were sequenced.
Screening of BAC clones
Human BAC library release III (Research Genetics) was screened by a PCR method. From the 3Ј-RACE sequences, the following PCR primers were obtained; N and O for HOXD13 (T1-3Ј), I and J for FN1 (T2-3Ј). PCR amplification was carried out for 35 cycles (denaturation at 94°C for 20 s, annealing at 58°C for 40 s, and extension at 72°C for 60 s). Isolated BAC clones were cultured in LB medium, and DNA was prepared by standard techniques.
Genomic cloning
For NUP98, a previously isolated P1 clone, 7 P189, was used. We have determined the exon-intron structure of NUP98 (manuscript in preparation). The numbering of exons and introns of NUP98 was done according to these data. The 3Ј-genomic walking from exon 12 of NUP98 was performed using the GenomeWalker Kit (Clontech). PCR amplification between primer B of NUP98 exon 12 and adaptor primer AP1 was carried out according to the protocol of the manufacturer, and we obtained PCR products of 1.5 kb and 2.9 kb. These amplimers were cloned into the pGEM-T vector, and were sequenced and aligned. We developed a PCR primer pair of NXF3 and NXR3 using this genomic sequences, and obtained a single copy probe (NP-gfx3) for intron 12 of NUP98 as a 368 bp PCR product amplified using the primers. DNA from P189 was digested with EcoRI and the 2.5 kb fraction was subcloned into the pUC118 vector (Takara Shuzo, Mie, Japan), and we obtained a clone (NUP#E5-49) containing a part of intron 12 of NUP98 using NP-gfx3 as a probe. For HOXD13, 6 kb EcoRI fragments were subcloned from the BAC CTC-215c6 into a pUC118 vector. We PCR-amplified a probe for FN1 with primers I and J. The clones were screened using the probe, and one clone (RB79#E6-6a) was obtained. Next, 5Ј and 3Ј genomic walkings from this 6 kb EcoRI fragment containing a part of FN1 were performed. The LM-PCR method was used for 5Ј walking as described previously. 7 In brief, BAC clones were digested with EcoRV, PvuII or RsaI and ligated with the pre-annealed linker. The ligated mixtures were amplified by PCR using a linker primer LM1 and specific primer H from RB79#E6-6a, and a 1530 bp PCR product was produced. The long range PCR (LR-PCR) method was used for 3Ј walking using Platinum Taq Pfx DNA polymerase (Gibco BRL). Genomic DNA was amplified with primers K and M, and a 1928 bp PCR product was produced. The amplified fragments were sequenced, aligned and used as probes for Southern blot analysis.
Amplification and analysis of genomic DNA fragments spanning t(2;11) breakpoints
The primers for PCR amplification of genomic DNA spanning the breakpoint regions were designed according to the germline sequences. In the case of der(11) (NUP98-FN1/HOXD13), a primer pair of C and G was used, and in the case of der(2) (FN1/HOXD13-NUP98), a primer pair of F and D was used. PCR amplification was carried out for 35 cycles (denaturation at 94°C for 20 s, annealing at 58°C for 40 s, and extension at 72°C for 60 s). The resulting breakpoint amplimers were directly sequenced and compared with the wild-type genomic sequences of FN1/HOXD13 and NUP98.
DNA sequencing
DNA sequences of PCR products and plasmids were determined using a Thermo Sequenase II kit (AmershamPharmacia) and a 373S DNA sequencer (Perkin Elmer). DNA sequences were analyzed using MacVector program (Oxford Molecular, Oxford, UK) and Repeat Masker program (http://ftp.genome.washington.edu/cgi-bin/RepeatMasker). Searches for homology against nucleotide and amino acid sequence databases were performed using BLAST and BLASTP, respectively.
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Results
Cloning of fusion transcripts in t(2;11) leukemia
The patient was diagnosed as having de novo AML (M4) at 62 years of age. Cytogenetic analysis of leukemia cells from the patient showed the presence of t(2;11)(q31;p15). The NUP98 gene on chromosome 11p15 is frequently involved in leukemias with 11p15-related translocations. Thus, we examined for gene rearrangement of NUP98. Most NUP98 breakpoints occur between exons 12 and 13 (former names, exons B and C) except in the inv(11) type of leukemia. [7] [8] [9] [10] [11] Southern blot analysis of EcoRI-digested genomic DNA from the bone marrow cells of the patient revealed a rearranged band of 2.2 kb and a germline 2.5 kb band using the NUP98 intron 12 probe, NP-gfx3 (Figure 1a) . Recent reports revealed that the N-terminal portion of NUP98 is fused to the C-terminal portion of other proteins in certain leukemias with 11p15 translocations. [7] [8] [9] [10] [11] Therefore, a 3Ј-RACE PCR method was used to determine the partner gene fused to NUP98 on chromosome 2q.
Two RACE products of different sizes were identified, and designated as type I and type II fusion transcripts. Sequence analysis revealed that the sequence of the 3Ј portion of the type I PCR product (T1-3Ј) was identical to a part of the cDNA sequence of human homeobox gene HOXD13 on chromosome 2q31 (Figure 1b) . This sequence originated from exon 2 of HOXD13, which encodes the entire homeodomain region. This fusion transcript was the same as reported previously. 8 The 3Ј portion of the type II PCR product (T2-3Ј) did not show any significant homology to any known gene or EST in the GenBank DNA sequence database. However, it was found to be located on chromosome 2q by PCR mapping Leukemia using chromosome hybrid panels (data not shown). We named this novel putative gene as FN1 (fused gene 1 to NUP98). By RT-PCR analysis, FN1 was expressed at a low level in fetal liver and fetal kidney, but not in peripheral blood leukocytes or bone marrow. As described later, FN1 was mapped between HOXD13 and another homeobox gene, EVX2. No RT-PCR product was amplified using primers between FN1 and HOXD13 or between FN1 and EVX2. In Northern analysis of normal human fetal tissues, FN1 expression was detected as 1.8 kb and 2.3 kb transcripts in fetal liver and as a 1.8 kb transcript in fetal kidney, but no transcript was detected in fetal brain or fetal lung (Figure 1c) . Although we did not succeed in obtaining the full-length cDNA, FN1 has a putative ORF that would encode a 51 amino acid peptide. The fusion gene NUP98-FN1 is expected to alter this reading frame of NF1 and to change the Cterminal 450 amino acids of NUP98 into a 12 amino acid peptide of unknown significance.
Next, we confirmed by RT-PCR that the formation of the two chimeric transcripts was an outcome of the t(2;11) translocation. PCR primers were designed from the 5Ј end of NUP98 and from the 3Ј end of HOXD13 and FN1. RT-PCR, which can amplify the two fusion transcripts, NUP98-HOXD13 and NUP98-FN1, gave products of 362 bp and 386 bp, respectively, which were the expected sizes from the RNA of the patient, but not from the RNA of healthy controls or other leukemia cells lacking t(2;11) (inv11-1 and inv11-2; leukemic patients with inv(11)(p15q22), in which NUP98 is fused to DDX10) (Figure 2a) . NUP98 is expressed ubiquitously. 7 Thus, these two fusion transcripts are presumed to encode two types of chimeric protein driven by the NUP98 promoter in this type of leukemia (Figure 2b ).
Ectopic expression of wild-type HOXD13 in t(2;11) leukemia
Previous reports showed that most of the HOX A, B, and C cluster genes, but not the HOX D cluster genes, were normally expressed in CD34 + marrow cells, including primitive and lineage-committed progenitors. 15, 16 This indicated that HOXD13 was normally down-regulated in mature myeloid cells. Thus, we examined the expression of wild-type HOXD13 by RT-PCR in the patient with t(2;11) leukemia and in three patients with other leukemias; two patients with inv(11)(p15q22) and one patient without the NUP98 rearrangement. Interestingly, the expression of wild-type HOXD13 was detected with the expected product size (659 bp) in the patient with t(2;11) leukemia, but not in patients with leukemias other than t(2;11) (Figure 2c ). Sequencing analysis confirmed that the product originated from wild-type HOXD13. This result reveals that up-regulation of wild-type HOXD13 occurs in t(2;11) leukemia in addition to the expression of the two fusion transcripts, NUP98-HOXD13 and NUP98-FN1.
Splicing variants of NUP98
To obtain a NUP98-HOXD13 fusion cDNA encoding the predicted chimeric oncoprotein, we performed RT-PCR using primers NH17 and Hxd13H1, which were designed to amplify the predicted 1659 bp full-length ORF of the fusion transcript. The PCR products were then cloned and sequenced. Two out of 20 clones showed a novel 51 bp in-frame insertion within the NUP98 portion of the fusion transcript (DDBJ/GenBank Accession No. AB038155). Because this insertion adds 17 amino acids, including one FG repeat to NUP98, the fusion gene encodes a protein consisting of the N-terminal part of NUP98 with the 38 FG repeats and the C-terminal part of HOXD13 with the homeodomain (Figure 2b ). Although Kasper et al 17 reported an alternatively spliced short isoform of NUP98 (NUP98b) containing only 19 FG repeats in bone marrow cells from a healthy control and from a leukemia patient with t(7;11), we did not detect such a product in this patient. RT-PCR analysis of human normal tissues revealed that the insertion originated from a wild-type splicing variant of NUP98 (Figure 3 ).
Genomic structure of the translocation breakpoints
To determine the genomic loci of the HOXD13 and FN1 genes on chromosome 2, we screened a BAC genomic library using the 3Ј-RACE products (T1-3Ј and T2-3Ј) as probes. The two probes identified the same BAC clones (CTC-215c6 and ). An EcoRI restriction map was developed using genomic DNAs from the BACs, cell lines and normal peripheral blood cells (Figure 4) . The exon 2 of HOXD13 was mapped on a 10 kb EcoRI fragment. Another homeobox gene EVX2 (eve-related gene) was reported to be located at about 13 kb upstream from HOXD13. 18 
EVX2 is transcribed in an opposite
Leukemia orientation as compared to that of HOXD13. This gene was mapped on a 15 kb EcoRI fragment as shown in Figure 4 . FN1 was mapped on a 6 kb EcoRI fragment. We subcloned and sequenced this 6 kb EcoRI fragment, and then applied genomic walking from the fragment by using the PCR method. As a result, a 1.5 kb fragment for the 5Ј direction and a 1.9 kb frag- The major breakpoint cluster of NUP98 occurs in intron 12 (former name, intron B). The size of this intron is about 9 kb. To obtain genomic clones containing intron 12, we performed 3Ј-genomic walking from exon 12 by PCR. We isolated two overlapping clones, WdT-2 (2.9 kb) and WdT-4 (1.5 kb), and sequenced them. The NP-gfx3 probe, which was developed from the sequence, detected the rearrangement of NUP98 as shown in Figure 1a . The breakpoint was located in a 2.5 kb EcoRI fragment. From a P1 clone containing part of the NUP98 gene, P189, we subcloned the 2.5 kb EcoRI fragment NP#E5-49, and sequenced it. In all, we obtained 3.3 kb of genomic sequence around the breakpoint of NUP98, including exon 12 (DDBJ/GenBank accession No. AB038344). The repetitive sequence content is very high (62%). There are five SINE repeats (five Alu), one DNA transposon (MER, which is divided into three parts by Alu insertions) and two LINE repeat (two HAL) as shown in Figure 5a .
Identification of the chromosomal breakpoint
To determine the junction sequences of the chromosomal breakpoints of t(2;11), we performed genomic PCR analysis of the patient's DNA using primers designed from the genomic sequences of NUP98, HOXD13 and FN1. We identified both der(11) and der(2) genomic fragments as the NUP98-FN1/HOXD13 fragment and the FN1/HOXD13-NUP98 fragment, respectively. In the case of der(11) (NUP98-FN1/HOXD13), a 331 bp product was generated with primers C and G. In the case of der(2) (FN1/HOXD13-NUP98), a 433 bp product was generated with primers F and D. The PCR products were directly sequenced. A comparison of these breakpoint sequences and germline sequences is shown in Figure 5c . In both the NUP98-FN1/HOXD13 and FN1/HOXD13-NUP98 fragments, the breakpoints in NUP98 were found within a LINE repetitive sequence, HAL1. The translocation is reciprocal but not balanced at the fine structural level. Comparison of the two derivative chromosomes indicated duplication of genomic sequences between der(2) and der(11) chromosomes (Figure 5b ). The duplicated sequence is 49 bp for 11p15 and 110 bp for 2q31. A short stretch (TCT) of homology between 11p15 and 2q31 was observed at the breakpoint junction in the der(11) chromosome. At least 6/7 match to the consensus-heptamer recognition sequences for V(D)J recombinase binding 20 were
Leukemia observed near the breakpoint junction in chromosome 2, but no obvious nonamer sequences 20 were found (Figure 5c ).
Discussion
In this study, we found two kinds of fusion transcript, NUP98-HOXD13 and NUP98-FN1, in de novo leukemia (AML M4) with t(2;11)(q31;p15). In this leukemia, heterogeneous chim-eric transcripts between NUP98 at 11p15 and two genes at 2q31, FN1 and HOXD13, were generated via intergenic splicing and alternative splicing. Recently, Raza-Egilmez et al 8 reported a NUP98-HOXD13 fusion transcript in a case of therapy-related leukemia (t-AML M6). In both cases, the t(2;11) translocation was the sole cytogenetic abnormality seen in the leukemic cells. These data indicate that formation of the NUP98-HOXD13 fusion gene is a rare but recurrent event in de novo and therapy-related AML. The predicted structure of the NUP98-HOXD13 protein is similar to those of NUP98-HOXA9 and NUP98-PMX1 fusion proteins. Therefore, this fusion protein might work as an oncoprotein like NUP98-HOXA9 and NUP98-PMX1 in leukemia. Another fusion gene, NUP98-FN1, encodes a chimeric protein consisting of the N-terminal half of NUP98 and the C-terminal 12 amino acid region of an unknown protein. Although the full-length cDNA has not been isolated, FN1 has a putative ORF encoding 51amino acids. The fusion gene NUP98-FN1 is expected to alter this reading frame of NF1 and change the C-terminal 450 amino acids of NUP98 into a region of 12 amino acids of unknown significance. This leads to two possible interpretations about the oncogenic potential of the NUP98-FN1 fusion gene. One is that it may not produce a functional chimeric protein, and the other is that it may produce a chimeric protein that might interfere with the normal function of NUP98. Besides this study, intergenic splicing and the production of multiple fusion transcripts have been consistently reported in leukemias with the t(3;21)(q26;q22) translocation. 21, 22 In this translocation, the AML1 gene at 21q22 can fuse with three other genes at 3q26, namely EAP1, MDS1 and EVI1. Although the 3q26 genes are located over a region of 400 kb, fusion transcripts AML1-EAP1, AML1-MDS1 and AML1-EVI1 were detected in t(3;21) leukemia. These fusion genes encode fusion proteins with AML1, but the AML1-EAP1 fusion does not maintain the EAP1 reading frame, and a stop codon is introduced shortly after the junction. 23 Functional analyses revealed that both AML1-MDS1 and AML-EAP1 fusion proteins acted as inhibitors of normal AML1, but that only AML1-MDS1 had tumor-promoting properties. 24 Further studies on the function of NUP98-FN1 will be required to determine the role of this fusion gene in tumor development.
NUP98 is a 98 kDa nucleoporin. Another nucleoporin gene, NUP214/CAN, is also involved in other translocations in leukemia. 25, 26 The N-terminal domain of NUP98 and the Cterminal domain of NUP214 contain characteristic FG repeat motifs. In all fusion genes involving NUP98 and NUP214 in leukemia, the FG repeats are retained in the predicted, functional fusion proteins. The NUP98-HOXA9 fusion protein transforms NIH3T3 cells, and this transforming ability is retained when the FG repeat region from NUP98 is exchanged for that of NUP214. 17 These results suggest that FG repeats are important in leukemogenesis. We identified a novel form of the NUP98-HOXD13 transcript in which a 51 bp novel exon was inserted into the NUP98 portion. This fusion gene carries one more FG, resulting in a NUP98 product with 38 FG repeats fused to the homeodomain of HOXD13. The 51 bp insertion was also observed in normal human tissues, so the insertion might be from a wild-type splicing variant of NUP98. It remains unclear whether or not these different fusion proteins with various numbers of FG repeats actually display altered leukemogenic activity.
Mutation of HOXD13 was reported to be involved in an inherited disorder, synpolydactyly. 27, 28 This disease is caused by expansions of a polyalanine stretch in the N-terminal region of HOXD13. In a leukemic fusion protein, NUP98-HOXD13, the homeobox DNA binding domain is retained, but the N-terminal region containing the polyalanine stretch is lost. HOXD13 is not normally expressed in bone marrow cells. 15, 16 Thus, loss of the polyalanine stretch and ectopic expression of homeodomain of HOXD13 by fusion with the NUP98 N-terminal domain might cause deregulated transcriptional activity of the fusion protein in leukemia. Furthermore, wild-type HOXD13 was also shown to be ectopically expressed in the t(2;11) leukemia described here. Up-regulation of HOXD13 might be associated with leukemogenesis in this type of leukemia.
One of the two t(2;11) cases, three of the five inv(11) cases, the t(1;11) case, and both the t(11;20) cases were secondary leukemias that arose after treatment of the primary neoplasms by chemotherapy with topoisomerase II (topo II) inhibitors. Moreover, NUP98 was reported to be associated with childhood t-AML/MDS. 12 However, other mechanisms of recombination have been proposed such as homologous recombination via Alu repeats, 29 alternating purine pyrimidine tracts, 30 heptamer-nonamer V-D-J recombinase, 20 and binding of translin. 31 We have determined the genomic structure of chromosomal breakpoints and identified features of the DNA sequences around the breakpoints in de novo AML with t(2;11). There are no apparent topo II binding sequence 32 near the breakpoints in this de novo leukemia. The presence of duplication at the breakpoints was observed, and the breakpoint of NUP98 was found to be within a LINE element. A LINE element was previously reported to lie at the breakpoint of NUP214 in t(6;9) leukemia. 33 Thus, it is suggested that double strand breaks with protruding ends are generated to undergo translocation, and that the LINE repeats play a role in the translocation event. Although this is not a lymphoid malignancy, consensus heptamer sequences for V(D)J recombinase binding were observed near the translocation breakpoints of 2q31. However, these matches were present only on one allele, so it unlikely that the V(D)J recombinase activity is directly involved in the genesis of this translocation.
The genomic maps, DNA sequences and primers described in this paper should allow rapid and easy detection of the genomic breakpoint of the t(2;11) translocation. We hope that this detailed knowledge of the breakpoint regions of the genes NUP98, HOXD13 and FN1 will facilitate the analyses of other gene fusions in t(2;11) leukemia.
